IDEAYA Biosciences Past Earnings Performance
Past criteria checks 0/6
IDEAYA Biosciences's earnings have been declining at an average annual rate of -39.8%, while the Biotechs industry saw earnings growing at 19.8% annually. Revenues have been growing at an average rate of 8.6% per year.
Key information
-39.8%
Earnings growth rate
-2.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 8.6% |
| Return on equity | -25.9% |
| Net Margin | -3,921.1% |
| Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
Recent updates
Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later
Apr 16Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth?
Apr 13
Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming
Feb 10We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth
Jan 03Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash
Dec 04Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
Sep 20Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?
Jul 08Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'
Jun 18Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?
Feb 22Ideaya Biosciences: A Strong Bet In Targeted Oncology
Feb 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
Nov 09Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Oct 03IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans
Jul 04We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate
Mar 10Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Nov 04Revenue & Expenses Breakdown
How IDEAYA Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 24 | 7 | -274 | 39 | 0 |
| 30 Sep 24 | 4 | -178 | 35 | 0 |
| 30 Jun 24 | 12 | -154 | 34 | 0 |
| 31 Mar 24 | 16 | -129 | 30 | 0 |
| 31 Dec 23 | 23 | -113 | 28 | 0 |
| 30 Sep 23 | 23 | -103 | 27 | 0 |
| 30 Jun 23 | 45 | -74 | 26 | 0 |
| 31 Mar 23 | 47 | -68 | 24 | 0 |
| 31 Dec 22 | 51 | -59 | 24 | 0 |
| 30 Sep 22 | 50 | -53 | 23 | 0 |
| 30 Jun 22 | 29 | -66 | 22 | 0 |
| 31 Mar 22 | 32 | -55 | 21 | 0 |
| 31 Dec 21 | 28 | -50 | 20 | 0 |
| 30 Sep 21 | 36 | -37 | 19 | 0 |
| 30 Jun 21 | 36 | -30 | 17 | 0 |
| 31 Mar 21 | 27 | -31 | 17 | 0 |
| 31 Dec 20 | 20 | -34 | 15 | 0 |
| 30 Sep 20 | 9 | -40 | 14 | 0 |
| 30 Jun 20 | 0 | -46 | 13 | -17 |
| 31 Mar 20 | 0 | -44 | 11 | -8 |
| 31 Dec 19 | 0 | -42 | 10 | 0 |
| 30 Sep 19 | 0 | -40 | 9 | 8 |
| 30 Jun 19 | 0 | -42 | 7 | 37 |
| 31 Mar 19 | 0 | -38 | 6 | 35 |
| 31 Dec 18 | 0 | -34 | 5 | 0 |
Quality Earnings: IDYA is currently unprofitable.
Growing Profit Margin: IDYA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IDYA is unprofitable, and losses have increased over the past 5 years at a rate of 39.8% per year.
Accelerating Growth: Unable to compare IDYA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IDYA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (38.5%).
Return on Equity
High ROE: IDYA has a negative Return on Equity (-25.91%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 13:10 |
| End of Day Share Price | 2025/05/05 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IDEAYA Biosciences, Inc. is covered by 26 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Zhiqiang Shu | Berenberg |
| Suranjit Mukherjee | BTIG |